Investor Webinar: HOPE<sup>®</sup> 1 SPV created to fund Ph.2 and Ph.3 US FDA trials

Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.

Start typing and press Enter to search

Shopping Cart